Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | PTGIR | P43119 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP12 | P39900 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | MMP16 | P51512 | 1/20 | 0.39 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31518126 | 0.83 | AKR1B1 (0.47) | AKR1B1TDP1L3MBTL1PTGS2NPSR1 | |
| SCHEMBL8893994 | 0.80 | PTPN1 (0.49) | TDP1L3MBTL1ATMALDH1A1HPGD | |
| SCHEMBL3276086 | 0.78 | L3MBTL1 (0.61) | TDP1L3MBTL1ATMNPSR1KMT2A | |
| SCHEMBL2092803 | 0.76 | L3MBTL1 (0.43) | PTGIRTDP1L3MBTL1ATMNPSR1 | |
| SCHEMBL12075221 | 0.75 | KDM4E (0.42) | AKR1B1L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL7339780 | 0.74 | NPC1 (0.55) | TDP1ATMNPSR1KMT2AMEN1 | |
| SCHEMBL2558366 | 0.73 | AKR1B1 (0.55) | AKR1B1TDP1PTGS2BCAT2ALDH1A1 | |
| SCHEMBL2089007 | 0.73 | PTGIR (0.41) | PTGIRTDP1L3MBTL1ATMNPSR1 | |
| SCHEMBL2098123 | 0.72 | ESR1 (0.43) | PTGIRTDP1L3MBTL1ATMNPSR1 | |
| SCHEMBL30500285 | 0.72 | ALDH1A1 (0.46) | TDP1L3MBTL1ATMNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2067772-B1 | Dibenzo (b,f) azepine intermediates | NOVARTIS AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2067772-A2 | Dibenzo [b,f] azepine intermediates and their preparation | Novartis Ag (CH) | 2009-06-10 | — | — | EP | disclosed |
| EP-1265868-B1 | Preparation of DIBENZO[B,F]AZEPINE INTERMEDIATES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| CN-100455572-C | Dibenzo(b,f)azepine derivatives | NOVARTIS AG (CH) | 2009-01-28 | — | — | CN | disclosed |
| US-7112673-B2 | Dibenzo [b,f]azepine intermediates | NOVARTIS AG (CH) | 2006-09-26 | — | — | US | disclosed |
| CN-1244563-C | Dibenzo [ b, f ] azepine intermediates | NOVARTIS AG (CH) | 2006-03-08 | — | — | CN | disclosed |
| CN-1721409-A | Dibenzo(b,f)azepine derivatives | NOVARTIS AG (CH) | 2006-01-18 | — | — | CN | disclosed |
| US-20030032800-A1 | Dibenzo(b,f)azepine derivatives and their preparation | NOVARTIS PHARMACEUTICALS CORPORATION | 2003-02-13 | — | — | US | disclosed |
| CN-1394204-A | Dibenzo [ b, f ] azepine intermediates | NOVARTIS AG (CH) | 2003-01-29 | — | — | CN | disclosed |
| EP-1265868-A2 | DIBENZO (B,F) AZEPINE INTERMEDIATES | Novartis AG (CH) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001056992-A2 | DIBENZO (B,F) AZEPINE INTERMEDIATES | NOVARTIS AG (CH) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032800-A1 | Dibenzo(b,f)azepine derivatives and their preparation | MAOB, BBOX1, QDPR | AKR1B1 759/4885PTGIR 975/4885TDP1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.